Zevtera (ceftobiprole) is a broad-spectrum cephalosporin antibiotic indicated for the treatment of community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia).
Ceftobiprole medocaril sodium, the active ingredient of Zevtera, is the prodrug of ceftobiprole. Similar to other beta lactams, ceftobiprole is bactericidal and works by binding to penicillin-binding proteins in susceptible species, inhibiting synthesis of the peptidoglycan cell wall. Ceftobiprole is inactive against Enterobacteriaceae, Acinetobacter and P. aeruginosa strains that express β-lactamases of Ambler class A, B or D.
Ceftobiprole is administered as a 500mg intravenous infusion over 2 hours every 8 hours. In community-acquired pneumonia it may be suitable to switch the patient to an oral antibiotic after at least 3 days of ceftobiprole treatment, depending on their response.
The most common adverse effects of ceftobiprole are nausea, vomiting, diarrhoea, infusion site reactions, hypersensitivity and dysgeusia.